Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11413487 | 0.84 | CA1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7933110 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19475057 | 0.80 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14154163 | 0.79 | LMNA (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1101657 | 0.78 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22863705 | 0.78 | MMP8 (0.40) | CA12CA1CA2CA9LMNA | |
| SCHEMBL12128674 | 0.78 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1121160 | 0.77 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7932932 | 0.77 | ALDH1A1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7928469 | 0.77 | ALDH1A1 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024247648-A1 | TUMOR THERAPEUTIC AGENT, AND COMPLEX | 学校法人兵庫医科大学 | 2024-12-05 | — | — | WO | disclosed |
| US-20240002398-A1 | COMPLEX, AND USE THEREOF | RIKEN (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4233916-A1 | COMPLEX, AND USE THEREOF | RIKEN (JP) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022085523-A1 | COMPLEX, AND USE THEREOF | 国立研究開発法人理化学研究所 | 2022-04-28 | — | — | WO | disclosed |
| EP-0661350-B1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON CATALYTIC CHEM IND (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-5968688-A | RESINS AND DYES FOR COLOR FILTERS | NIPPON SHOKUBAI CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5817843-A | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0833203-A1 | Color filter grade photosensitive resin coloring composition, and color filter using the same | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
| EP-0661350-A1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002398-A1 | COMPLEX, AND USE THEREOF | ACR, C9, APEX1 | CA12 388/4885CA1 62/4885CA2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.